While the world debates the ethics of gene editing, a tiny team in a lab is solving the hardest problem of all: how to get the cure where it needs to go. Editpep isn't just another biotech startup; it's a precision instrument for delivery.

"The breakthrough isn't the editor; it's the envelope. Editpep is building the FedEx for gene therapy."

The tech stack reveals a modern, lean operation. Using Squarespace for a landing page is standard, but the inclusion of Stimulus and Tailwind CSS suggests a team that values lightweight, maintainable code—perhaps a digital tool for experimental design or data visualization. The lack of traffic (0 monthly visits) is a feature, not a bug; they are building for regulators and partners, not consumers.

• Extreme team leverage: 4 people managing a complex biotech platform
• Revenue indicates early commercialization or grant funding, not VC scale yet
• Zero web traffic suggests a closed-door R&D strategy
• Focus on 'potency' implies high-efficacy data in animal models